抑郁症药物治疗的研究进展  

Research Progress in Drug Therapy for Depression

作　　者：汪洋 郭飞 夏明钰[1] Wang Yang;Guo Fei;Xia Mingyu(Shenyang Pharmaceutical University,Shenyang 110016,China;Nantong Aozekang Pharmaceutical Technology Co.,Ltd.,Nantong 226100,China)

机构地区：[1]沈阳药科大学,辽宁沈阳110016 [2]南通奥泽康医药科技有限公司,江苏南通226100

出　　处：《山东化工》2024年第13期156-160,164,共6页Shandong Chemical Industry

摘　　要：在过去的70年里,抑郁症的药物治疗一直以单胺能假说为基础,近几年人们把目光从单胺类靶点转移到多靶点再摄取抑制剂和非单胺类靶点的药物开发。本文综述了近年来进入临床或已上市的相对较新的抗抑郁药物:盐酸羟哌吡酮、盐酸托鲁地文拉法辛、赛洛西宾、氯胺酮/S-氯胺酮、右美沙芬-安非他酮和布瑞诺龙/祖拉诺龙的临床前机制研究和临床药效评价,总结近年来抑郁症药物治疗的研究进展,希望能对抑郁症药物的下一步研究提供方向。In the past 70 years,drug therapy for depression has been based on the monoamine hypothesis.In recent years,people have shifted their focus from monoamine targets to the development of multi target reuptake inhibitors and non monoamine target drugs.This article reviews the relatively new antidepressant drugs that have entered clinical practice or have been marketed in recent years:preclinical mechanism research and clinical efficacy evaluation of hypidone hydrochloride,toludesvenlafaxine hydrochloride,psilocybin,ketamine/S-ketamine,dextromethorphan-bupropion,brexanolone/zuranolone,summarizing the research progress of depression drug treatment in recent years,hoping to provide direction for the next step of depression drug research.

关 键 词：抗抑郁药物 血清素受体 非单胺类靶点 N-甲基-D-天冬氨酸受体 离子型γ-氨基丁酸受体 

分 类 号：TQ463[化学工程—制药化工] R749[医药卫生—神经病学与精神病学]